Inari Medical (NARI)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.48 (-0.93%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Inari Medical (NARI)
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.

Key Insights

Critical company metrics and information
  • Share Price

    $51.08
  • Market Cap

    $2.99 Billion
  • Total Outstanding Shares

    58.54 Million Shares
  • Total Employees

    1,300
  • Dividend

    No dividend
  • IPO Date

    May 22, 2020
  • SIC Description

    Surgical & Medical Instruments & Apparatus
  • Homepage

    https://www.inarimedical.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2023 to June 30, 2024
MetricValue
Net Cash Flow From Financing Activities$681000.00
Net Cash Flow From Investing Activities$-14.49 Million
Net Cash Flow From Operating Activities$27.41 Million
Exchange Gains/Losses$125000.00
Net Cash Flow, Continuing$12.23 Million
Net Cash Flow From Financing Activities, Continuing$681000.00
Net Cash Flow From Investing Activities, Continuing$-14.49 Million
Net Cash Flow From Operating Activities, Continuing$27.41 Million
Net Cash Flow$12.36 Million

Income Statement

July 1, 2023 to June 30, 2024
MetricValue
Diluted Earnings Per Share$0.99
Selling, General, and Administrative Expenses$406.99 Million
Revenues$547.47 Million
Research and Development$96.17 Million
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss$-57.05 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Expenses$523.91 Million
Basic Earnings Per Share$0.98
Diluted Average Shares$114.90 Million
Operating Income/Loss$-46.80 Million
Income/Loss From Continuing Operations Before Tax$-35.09 Million
Costs And Expenses$582.57 Million
Net Income/Loss Available To Common Stockholders, Basic$-57.05 Million
Income Tax Expense/Benefit$21.96 Million
Basic Average Shares$115.72 Million
Gross Profit$477.11 Million
Net Income/Loss Attributable To Parent$-57.05 Million
Cost Of Revenue$70.37 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Benefits Costs and Expenses$582.57 Million
Income/Loss From Continuing Operations After Tax$-57.05 Million

Balance Sheet

July 1, 2023 to June 30, 2024
MetricValue
Fixed Assets$23.00 Million
Intangible Assets$143.11 Million
Current Liabilities$138.26 Million
Equity Attributable To Parent$423.81 Million
Assets$672.93 Million
Other Non-current Assets$257.47 Million
Inventory$49.36 Million
Accounts Payable$16.38 Million
Equity Attributable To Noncontrolling Interest$0.00
Equity$423.81 Million
Wages$54.36 Million
Current Assets$249.35 Million
Noncurrent Liabilities$110.86 Million
Other Current Liabilities$67.52 Million
Other Current Assets$199.99 Million
Liabilities$249.12 Million
Noncurrent Assets$423.58 Million
Liabilities And Equity$672.93 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.